A Study for the PanCystPro Assay in the Management of Pancreatic Cystic Lesions
Start Date
2/17/2026
Completion Date
6/30/2027
Summary
The purpose of this research is to learn if the PanCystPro assay can help doctors in making decisions about treatment and monitoring of pancreatic cysts. The PanCystPro test measures glucose, carcinoembryonic antigen (CEA), and gastricsin biomarkers on fluid obtained from a pancreatic cyst. The test reports if the cyst fluid should be considered "Non-mucinous" or "Mucinous". Mucinous pancreatic cysts are more likely to progress to cancer while non-mucinous cysts seldom progress to cancer.
Detailed Description
A prospective observational study to assess the impact of PanCystPro in patients with radiographically confirmed pancreatic cysts planned for Endoscopic Ultra Sound (EUS) Fine Needle Aspirate (FNA). Eligible subjects will be enrolled after signing the ICF. One pancreatic cyst sample will be sent to the Amplified lab for PanCystPro testing. The impact of PanCystPro on clinical management intention will be assessed after the PanCystPro result has been received by the physician. One year after enrollment the actual clinical management the patient received will be assessed.
Eligibility Criteria
Age Range: 18 years to No maximum
Conditions
Locations
Indiana University
Indianapolis, Indiana 46202
United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts 02215
United States
Rutgers Health
New Brunswick, New Jersey 08901
United States